Press "Enter" to skip to content

U.S. group says Novartis MS drug price out of line with benefit

The Boston-based Institute for Clinical and Economic Review (ICER), which has been reviewing Mayzent for months, recommended that Novartis lower the drug’s price.

Original source:

Also Read:   Cipla to acquire 11.71% stake in Wellthy Therapeutics